Pharma: Other News To Note
Tuesday, January 8, 2013
Merck & Co. Inc., of Whitehouse Station, N.J., said its resubmitted new drug application for sugammadex sodium injection was accepted for review by the FDA. Merck expects the agency's review to be completed in the first half of this year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.